Spectral Medical (TSX: EDT)

Last close As at 05/08/2026

CAD1.40

−0.01 (−0.71%)

Market capitalisation

CAD411m

Spectral is a late-stage company seeking U.S. FDA approval for its proprietary product for the treatment of patients with septic shock, Toraymyxin (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can provoke sepsis, from the bloodstream. PMX is already approved for therapeutic use in Japan and Europe, and over 360,000 units were sold worldwide to date.

Market Data

Share Price CAD1.40
Market Cap CAD411m
52-Week High CAD1.84
52-Week Low CAD0.81
% Change 1M 2.9
% Change 6M 7.7
% Change 12M 70.7
Ave. Daily Volume 1yr 85,747

Sector

Healthcare

Equity Analyst

Key Management

  • Chris Seto

    CEO and Interim CFO

  • John A. Kellum

    Chief Medical Officer

Share Price Chart

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.